Plenty has been written about the opiod crisis in America wherein low income people are fed addictive drugs like OxyContin by greedy pharma companies. Therefore it should not surprise that some of these firms are paying massive fines to the US authorities: “Last month, the pharmaceutical giant Purdue Pharma pleaded guilty to charges related to the sale and marketing of the painkiller OxyContin. Even by the standards of corporate malpractice, the company’s behaviour, as detailed in a now-concluded federal investigation, is almost too sickening for words. Facing declining sales, it employed every tactic imaginable to skirt public health regulations and ensure that its flagship painkiller was sold and distributed as widely as possible: from aggressively marketing the highly addictive drug to offering kickbacks to doctors and defrauding federal health agencies. According to a press release issued by the Department of Justice, the penalties imposed on Purdue – which include a criminal fine of $3.5 billion and another $2 billion in criminal forfeiture – are the harshest ever levied against a pharmaceutical manufacturer.”
What is more surprising is the role played in this matter by a famous consulting firm: “Mentioned extensively, though not actually named, in the settlement document released by the DOJ in October is a “consulting company” said to have worked for Purdue since “approximately the mid-2000s.” Though anyone familiar with a recent lawsuit against the corporation pursued by the state of Massachusetts could probably have ventured a guess as to the mysterious firm’s identity, court filings obtained by the New York Times made it official late last month. As the Times reported:
Documents released … in a federal bankruptcy court in New York show that the adviser was McKinsey & Company, the world’s most prestigious consulting firm. The 160 pages include emails and slides revealing new details about McKinsey’s advice to members of the Sackler family, Purdue’s billionaire owners, and the firm’s now notorious plan to “turbocharge” OxyContin sales at a time when opioid abuse had already killed hundreds of thousands of Americans.”
The article goes on to laud the macabre brilliance of the McKinsey consultants: “Though the company has not been charged or sued by the federal government, its involvement in Purdue Pharma’s activities was clearly not passive or peripheral. As the settlement agreement released by the DOJ makes abundantly clear, McKinsey consultants worked closely with Purdue Pharma management both to identify the causes of declining sales and to formulate a strategy by which they could be reversed.
On the first score, their diagnosis was a simple one: “Both the reformulation and safeguards against medically unnecessary prescriptions” (in the settlement’s language) were to blame, and the “retail channel” (as the company informed Purdue Pharma) was “under intense scrutiny and direct risk.” In other words, increased awareness about the dangers of excessive OxyContin prescription had caused distributors and public authorities alike to become more cautious — a development which threatened to reduce profits. A 2014 budget presentation to Purdue Pharma’s board would subsequently identify newfound safeguards against the unnecessary prescription of opioids as “challenges” to its revenue goals.
….To help Purdue Pharma overcome declining sales, McKinsey consultants employed sophisticated analytics techniques to identify potential areas for increasing sales and rates of prescription such that the company’s marketing and distribution efforts could be targeted more effectively. Garnishing the initiative with the peppy, vaguely collegiate label “Evolve to Excellence,” McKinsey sent a memo to Purdue Pharma asking it to approve or reject E2E, which it suggested would “Turbocharge the Sales Engine.” As the settlement agreement details:
E2E took a multifaceted approach to increasing OxyContin prescribing and Purdue’s profits. The consulting company [McKinsey] recommended, among other strategies, refreshing Purdue’s marketing messaging – particularly around titration to higher, more lucrative dosages – and undertaking strategies to ensure prescriptions would be filled. At its core, however, E2E focused on intensifying marketing to the very highest-volume prescribers in the country…”
In case you are now feeling worked up about the whole thing, you shouldn’t because: “Having suddenly discovered ethics amid a growing PR disaster, McKinsey has since announced that it will no longer “advise any clients worldwide on opioid-specific business” and even issued a rare apology for its role in OxyContin sales.”
What is more surprising is the role played in this matter by a famous consulting firm: “Mentioned extensively, though not actually named, in the settlement document released by the DOJ in October is a “consulting company” said to have worked for Purdue since “approximately the mid-2000s.” Though anyone familiar with a recent lawsuit against the corporation pursued by the state of Massachusetts could probably have ventured a guess as to the mysterious firm’s identity, court filings obtained by the New York Times made it official late last month. As the Times reported:
Documents released … in a federal bankruptcy court in New York show that the adviser was McKinsey & Company, the world’s most prestigious consulting firm. The 160 pages include emails and slides revealing new details about McKinsey’s advice to members of the Sackler family, Purdue’s billionaire owners, and the firm’s now notorious plan to “turbocharge” OxyContin sales at a time when opioid abuse had already killed hundreds of thousands of Americans.”
The article goes on to laud the macabre brilliance of the McKinsey consultants: “Though the company has not been charged or sued by the federal government, its involvement in Purdue Pharma’s activities was clearly not passive or peripheral. As the settlement agreement released by the DOJ makes abundantly clear, McKinsey consultants worked closely with Purdue Pharma management both to identify the causes of declining sales and to formulate a strategy by which they could be reversed.
On the first score, their diagnosis was a simple one: “Both the reformulation and safeguards against medically unnecessary prescriptions” (in the settlement’s language) were to blame, and the “retail channel” (as the company informed Purdue Pharma) was “under intense scrutiny and direct risk.” In other words, increased awareness about the dangers of excessive OxyContin prescription had caused distributors and public authorities alike to become more cautious — a development which threatened to reduce profits. A 2014 budget presentation to Purdue Pharma’s board would subsequently identify newfound safeguards against the unnecessary prescription of opioids as “challenges” to its revenue goals.
….To help Purdue Pharma overcome declining sales, McKinsey consultants employed sophisticated analytics techniques to identify potential areas for increasing sales and rates of prescription such that the company’s marketing and distribution efforts could be targeted more effectively. Garnishing the initiative with the peppy, vaguely collegiate label “Evolve to Excellence,” McKinsey sent a memo to Purdue Pharma asking it to approve or reject E2E, which it suggested would “Turbocharge the Sales Engine.” As the settlement agreement details:
E2E took a multifaceted approach to increasing OxyContin prescribing and Purdue’s profits. The consulting company [McKinsey] recommended, among other strategies, refreshing Purdue’s marketing messaging – particularly around titration to higher, more lucrative dosages – and undertaking strategies to ensure prescriptions would be filled. At its core, however, E2E focused on intensifying marketing to the very highest-volume prescribers in the country…”
In case you are now feeling worked up about the whole thing, you shouldn’t because: “Having suddenly discovered ethics amid a growing PR disaster, McKinsey has since announced that it will no longer “advise any clients worldwide on opioid-specific business” and even issued a rare apology for its role in OxyContin sales.”
If you want to read our other published material, please visit https://marcellus.in/blog/
Note: The above material is neither investment research, nor financial advice. Marcellus does not seek payment for or business from this publication in any shape or form. The information provided is intended for educational purposes only. Marcellus Investment Managers is regulated by the Securities and Exchange Board of India (SEBI) and is also an FME (Non-Retail) with the International Financial Services Centres Authority (IFSCA) as a provider of Portfolio Management Services. Additionally, Marcellus is also registered with US Securities and Exchange Commission (“US SEC”) as an Investment Advisor.
